Article info

Download PDFPDF

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Authors

  1. Correspondence to Professor Josef S Smolen, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090 Vienna, Austria; josef.smolen{at}meduniwien.ac.at; Professor Peter Nash, Griffith University School of Medicine, Herston, Gold Coast, QLD 9726, Australia; drpnash{at}tpg.com.au
View Full Text

Citation

Nash P, Kerschbaumer A, Dörner T, et al
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Publication history

  • Received June 22, 2020
  • Revised September 11, 2020
  • Accepted September 14, 2020
  • First published November 6, 2020.
Online issue publication 
December 14, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.